Dataset: Gene expression profiling in psoriatic lesional and non-lesional skin [brodalumab treatment]
To explore the psoriasis phenotype and pathways involved in psoriasis, we characterized gene expression in lesional and non-lesional skin...
To explore the psoriasis phenotype and pathways involved in psoriasis, we characterized gene expression in lesional and non-lesional skin from psoriasis patients. Furthermore, we explored the effects of various doses of brodalumab on lesional skin over time. From each of the 25 psoriasis patients, we obtained two pre-dose biopsies, one from a lesion and the other from non-lesional skin in the same general body geography, and two post-dose biopsies. Total RNA was extracted from 6mm punch biopsies that were split in half. A total of 99 samples were run on Affymetrix HU133 Plus 2.0 microarrays. There was no paired non-lesional sample for 'T_lesional_pre-dose' (skn55789).
- Species:
- human
- Samples:
- 99
- Source:
- E-GEOD-53552
- Updated:
- Dec.12, 2014
- Registered:
- Sep.21, 2014
Factors:
(via ArrayExpress)
| Sample | PATIENT | TREATMENT | ORGANISM PART | TIME |
|---|---|---|---|---|
| GSM1296024 | K | 700mg brodalumab | lesional skin | day 15 |
| GSM1296025 | C | 700mg brodalumab | lesional skin | day 15 |
| GSM1296026 | F | placebo | lesional skin | day 15 |
| GSM1296027 | I | 700mg brodalumab | lesional skin | day 15 |
| GSM1296028 | X | 700mg brodalumab | lesional skin | day 15 |
| GSM1296029 | Z | 700mg brodalumab | lesional skin | day 15 |
| GSM1296030 | O | placebo | lesional skin | day 15 |
| GSM129603 | W | 700mg brodalumab | lesional skin | day 15 |
| GSM1296032 | J | 700mg brodalumab | lesional skin | day 15 |
| GSM1296033 | D | 700mg brodalumab | lesional skin | day 15 |
| GSM1296034 | A | 140mg brodalumab | lesional skin | day 15 |
| GSM1296035 | R | 140mg brodalumab | lesional skin | day 15 |
| GSM1296036 | T | placebo | lesional skin | day 15 |
| GSM1296037 | M | 350mg brodalumab | lesional skin | day 15 |
| GSM1296038 | U | 140mg brodalumab | lesional skin | day 15 |
| GSM1296039 | E | 350mg brodalumab | lesional skin | day 15 |
| GSM1296040 | S | placebo | lesional skin | day 15 |
| GSM129604 | G | 140mg brodalumab | lesional skin | day 15 |
| GSM1296042 | H | 350mg brodalumab | lesional skin | day 15 |
| GSM1296043 | L | 350mg brodalumab | lesional skin | day 15 |
| GSM1296044 | Q | 350mg brodalumab | lesional skin | day 15 |
| GSM1296045 | Y | 350mg brodalumab | lesional skin | day 15 |
| GSM1296046 | P | 350mg brodalumab | lesional skin | day 15 |
| GSM1296047 | B | 350mg brodalumab | lesional skin | day 15 |
| GSM1296048 | V | placebo | lesional skin | day 15 |
| GSM1296049 | K | 700mg brodalumab | lesional skin | day 43 |
| GSM1296050 | C | 700mg brodalumab | lesional skin | day 43 |
| GSM129605 | F | placebo | lesional skin | day 43 |
| GSM1296052 | I | 700mg brodalumab | lesional skin | day 43 |
| GSM1296053 | X | 700mg brodalumab | lesional skin | day 43 |
| GSM1296054 | J | 700mg brodalumab | lesional skin | day 43 |
| GSM1296055 | W | 700mg brodalumab | lesional skin | day 43 |
| GSM1296056 | O | placebo | lesional skin | day 43 |
| GSM1296057 | D | 700mg brodalumab | lesional skin | day 43 |
| GSM1296058 | Z | 700mg brodalumab | lesional skin | day 43 |
| GSM1296059 | A | 140mg brodalumab | lesional skin | day 43 |
| GSM1296060 | R | 140mg brodalumab | lesional skin | day 43 |
| GSM129606 | T | placebo | lesional skin | day 43 |
| GSM1296062 | M | 350mg brodalumab | lesional skin | day 43 |
| GSM1296063 | U | 140mg brodalumab | lesional skin | day 43 |
| GSM1296064 | E | 350mg brodalumab | lesional skin | day 43 |
| GSM1296065 | S | placebo | lesional skin | day 43 |
| GSM1296066 | G | 140mg brodalumab | lesional skin | day 43 |
| GSM1296067 | H | 350mg brodalumab | lesional skin | day 43 |
| GSM1296068 | Q | 350mg brodalumab | lesional skin | day 43 |
| GSM1296069 | L | 350mg brodalumab | lesional skin | day 8 |
| GSM1296070 | Y | 350mg brodalumab | lesional skin | day 8 |
| GSM129607 | P | 350mg brodalumab | lesional skin | day 8 |
| GSM1296072 | B | 350mg brodalumab | lesional skin | day 8 |
| GSM1296073 | V | placebo | lesional skin | day 8 |
| GSM1296074 | K | not specified | lesional skin | pre-dose |
| GSM1296075 | K | not specified | non-lesional skin | pre-dose |
| GSM1296076 | C | not specified | lesional skin | pre-dose |
| GSM1296077 | C | not specified | non-lesional skin | pre-dose |
| GSM1296078 | F | not specified | lesional skin | pre-dose |
| GSM1296079 | F | not specified | non-lesional skin | pre-dose |
| GSM1296080 | I | not specified | lesional skin | pre-dose |
| GSM129608 | I | not specified | non-lesional skin | pre-dose |
| GSM1296082 | X | not specified | lesional skin | pre-dose |
| GSM1296083 | X | not specified | non-lesional skin | pre-dose |
| GSM1296084 | Z | not specified | lesional skin | pre-dose |
| GSM1296085 | Z | not specified | non-lesional skin | pre-dose |
| GSM1296086 | O | not specified | lesional skin | pre-dose |
| GSM1296087 | O | not specified | non-lesional skin | pre-dose |
| GSM1296088 | W | not specified | lesional skin | pre-dose |
| GSM1296089 | W | not specified | non-lesional skin | pre-dose |
| GSM1296090 | J | not specified | lesional skin | pre-dose |
| GSM129609 | J | not specified | non-lesional skin | pre-dose |
| GSM1296092 | D | not specified | lesional skin | pre-dose |
| GSM1296093 | D | not specified | non-lesional skin | pre-dose |
| GSM1296094 | A | not specified | lesional skin | pre-dose |
| GSM1296095 | A | not specified | non-lesional skin | pre-dose |
| GSM1296096 | R | not specified | lesional skin | pre-dose |
| GSM1296097 | R | not specified | non-lesional skin | pre-dose |
| GSM1296098 | T | not specified | lesional skin | pre-dose |
| GSM1296099 | M | not specified | lesional skin | pre-dose |
| GSM1296100 | M | not specified | non-lesional skin | pre-dose |
| GSM129610 | U | not specified | lesional skin | pre-dose |
| GSM1296102 | U | not specified | non-lesional skin | pre-dose |
| GSM1296103 | E | not specified | lesional skin | pre-dose |
| GSM1296104 | E | not specified | non-lesional skin | pre-dose |
| GSM1296105 | S | not specified | lesional skin | pre-dose |
| GSM1296106 | S | not specified | non-lesional skin | pre-dose |
| GSM1296107 | G | not specified | lesional skin | pre-dose |
| GSM1296108 | G | not specified | non-lesional skin | pre-dose |
| GSM1296109 | H | not specified | lesional skin | pre-dose |
| GSM1296110 | H | not specified | non-lesional skin | pre-dose |
| GSM1296 | L | not specified | lesional skin | pre-dose |
| GSM1296112 | L | not specified | non-lesional skin | pre-dose |
| GSM1296113 | Q | not specified | lesional skin | pre-dose |
| GSM1296114 | Q | not specified | non-lesional skin | pre-dose |
| GSM1296115 | Y | not specified | lesional skin | pre-dose |
| GSM1296116 | Y | not specified | non-lesional skin | pre-dose |
| GSM1296117 | P | not specified | lesional skin | pre-dose |
| GSM1296118 | P | not specified | non-lesional skin | pre-dose |
| GSM1296119 | B | not specified | lesional skin | pre-dose |
| GSM1296120 | B | not specified | non-lesional skin | pre-dose |
| GSM129612 | V | not specified | lesional skin | pre-dose |
| GSM1296122 | V | not specified | non-lesional skin | pre-dose |